MedTrace Logo

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

NCT03817463 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 327624

Last updated 2024-09-23

Study results available
· View outcomes & findings →

Summary

Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor

Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor

DRUG

Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor

Dipeptidyl peptidase-4 (DPP-4) inhibitor

Sponsors & Collaborators

Principal Investigators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2021-12-10
Completion
2021-12-10
FDA Drug
Yes

Countries

  • Denmark
  • Finland
  • Germany
  • Israel
  • Japan
  • Norway
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03817463 on ClinicalTrials.gov